{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06028074",
            "orgStudyIdInfo": {
                "id": "GIM122-CT01"
            },
            "organization": {
                "fullName": "Georgiamune Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies",
            "officialTitle": "A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation With Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects With Advanced Solid Malignancies",
            "therapeuticArea": [
                "Other"
            ],
            "study": "safety-and-tolerability-study-of-gim-in-subjects-with-advanced-solid-malignancies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-31",
            "studyFirstSubmitQcDate": "2023-08-31",
            "studyFirstPostDateStruct": {
                "date": "2023-09-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-07",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Georgiamune Inc",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.",
            "detailedDescription": "This is a Phase 1/2, open label, first-in-human (FIH), multicenter, dose escalation study with enrichments and dose expansion cohorts at RP2D, designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of GIM-122 administered as a single agent in adults with advanced solid malignancies. This study will be conducted in 2 parts: Phase 1 or Part A (dose escalation and enrichment) and Phase 2 or Part B (dose optimization and cohort expansion)."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Malignancies"
            ],
            "keywords": [
                "solid tumor",
                "advanced malignancies",
                "GIM-122"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Part A: Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), Part B: Dose Expansion",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 111,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Intravenous administration of GIM-122",
                    "type": "EXPERIMENTAL",
                    "description": "GIM-122",
                    "interventionNames": [
                        "Drug: GIM122"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "GIM122",
                    "description": "GIM-122 administered IV once every 3 weeks",
                    "armGroupLabels": [
                        "Intravenous administration of GIM-122"
                    ],
                    "otherNames": [
                        "GIM-122"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose limiting toxicities [DLT] with GIM-122",
                    "description": "To identify dose limiting toxicities \\[DLT\\] with GIM-122",
                    "timeFrame": "18 months"
                },
                {
                    "measure": "Maximum tolerated dose [MTD] of GIM-122",
                    "description": "To identify maximum tolerated dose \\[MTD\\] of GIM-122",
                    "timeFrame": "18 months"
                },
                {
                    "measure": "Recommended Phase 2 Dose [RP2D] of GIM-122",
                    "description": "To identify Recommended Phase 2 Dose \\[RP2D\\] of GIM-122",
                    "timeFrame": "18 Months"
                },
                {
                    "measure": "Overall response rate (ORR) -Part B of the study",
                    "description": "To identify overall response rate (ORR) in patients with advanced malignant tumors who are refractory/ resistant to PD-1 and PD-L1 therapy",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Anti-tumor activity of GIM-122",
                    "description": "To assess anti-tumor activity of GIM-122 as a single agent in patients with advanced malignant tumors who are refractory/ resistant to PD-1 and PD-L1 therapy",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Incidence and severity of AE / SAEs and tolerability",
                    "description": "To assess incidence and severity of AE / SAEs and tolerability assessed by CTCAE grading",
                    "timeFrame": "36 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Area under the plasma concentration versus time curve (AUC)",
                    "description": "To preliminarily evaluate the AUC in patients with advanced malignant tumors",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Peak Plasma Concentration (Cmax)",
                    "description": "To preliminarily evaluate Cmax in patients with advanced malignant tumors",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Time of peak plasma concentration (Tmax)",
                    "description": "To preliminarily evaluate Tmax in patients with advanced malignant tumors",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Overall Response Rate (ORR) - Part A of the study",
                    "description": "To preliminarily evaluate ORR in patients with advanced malignant tumors",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Duration of response (DOR)",
                    "description": "To preliminarily evaluate DOR in patients with advanced malignant tumors",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Disease control rate (DCR)",
                    "description": "To preliminarily evaluate DCR in patients with advanced malignant tumors",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Best overall response (BOR)",
                    "description": "To preliminarily evaluate BOR in patients with advanced malignant tumors",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Progression-free survival (PFS)",
                    "description": "To preliminarily evaluate PFS in patients with advanced malignant tumors",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Overall survival (OS) rates at 12 months",
                    "description": "To preliminarily evaluate OS in patients with advanced malignant tumors at 12 Months",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Tumor expression of immunological markers",
                    "description": "To analyze tumor expression of immunological markers",
                    "timeFrame": "36 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nGeneral\n\n* Written informed consent\n* ECOG performance status 0-1.\n* Laboratory assessment 28 days prior to enrollment for assessment of acceptable cardiac, renal and hepatic functions\n* Recommended Double methods of contraception 90-days post treatment Cancer Specific\n* Histologically or cytologically confirmed locally advanced/unresectable or metastatic solid tumor\n* Received FDA approved treatment of PD-1 inhibitor or PD-L1 inhibitor for advance malignant tumors and have progressed/relapsed, are refractory, or intolerant\n* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1\n* Had prior therapy with PD-1/PD-L1 inhibitors. Other checkpoint inhibitors (ie, CTLA4, LAG3) are permitted if they did not lead to treatment discontinuation\n* No other lines of therapy that are available\n\nExclusion Criteria:\n\nGeneral\n\n* Enrolled in any other interventional clinical trial, starting within 4 weeks of the first dose of GIM-122 and throughout the duration of the study, or is receiving other therapy directed at their malignancy\n* Women who are pregnant or breastfeeding\n* History of cardiac issues, pulmonary embolism, active and clinically significant bacterial, fungal, or viral infection \u2264 6 months prior to dosing\n* Contraindications to the imaging assessments or other study procedures that subjects will undergo or any medical or social condition that, in the opinion of the investigator, might place a subject at an increased risk, affect compliance, or confound safety or other clinical study data interpretation Cancer Specific\n* Current second malignancy at other sites\n* Leptomeningeal disease\n* Spinal cord compression\n* Symptomatic or new or enlarging central nervous system (CNS) metastases\n\nTreatment-specific Exclusion Criteria\n\n* Ongoing toxicity \\> Grade 1 from prior therapy according to Common Terminology Criteria for Adverse Events (CTCAE) v 5.0\n* Has undergone a major surgery \\< 1 month prior to administration of GIM-122\n* Has received radiation therapy within 2 weeks prior to administration of GIM-122\n* Has undergone or is anticipated to undergo organ transplantation including allogeneic or autologous stem cell transplantation at any time\n* Has received systemic anti-cancer therapy within 2 weeks and cytotoxic agents that have a major delayed toxicity within 4 weeks, of the first dose of GIM-122\n* Prior treatment with other immune modulating agents within \\< 4 weeks prior to the first dose of GIM-122.\n* Has a diagnosis of immunodeficiency, either primary or acquired\n* Has received treatment with systemic steroids or any form of immunosuppressive therapy within 14 days prior to administration of GIM-122\n* Has active or prior history of autoimmune disease, including ulcerative colitis and Crohn's disease, or any condition that requires systemic steroids.\n* Has a known severe intolerance to or hypersensitivity reactions to monoclonal antibodies, Fc-bearing proteins, or IV immunoglobulin preparations; prior history of human anti-human antibody response; known allergy to any of the study medications, or excipients in the various formulations of any agent.\n* Has received live vaccines within 30 days of study initiation (inactivated vaccines are allowed; seasonal vaccines should be up to date \\> 30 days prior to administration of GIM-122).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "LumaBridge CRO",
                    "role": "CONTACT",
                    "phone": "210-563-8441",
                    "email": "contact@lumabridge.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Omid Hamid, MD",
                    "affiliation": "The Angeles Clinic and Research Institute",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "The Angeles Clinic and Research Institute",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90025",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "310-294-0438"
                        },
                        {
                            "name": "Omid Hamid, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Florida Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Sarasota",
                    "state": "Florida",
                    "zip": "34232",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kandyce Treijo",
                            "role": "CONTACT",
                            "phone": "941-377-9993"
                        },
                        {
                            "name": "Manish Rajni Patel, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.33643,
                        "lon": -82.53065
                    }
                },
                {
                    "facility": "Rutgers Cancer Institute of NJ",
                    "status": "RECRUITING",
                    "city": "New Brunswick",
                    "state": "New Jersey",
                    "zip": "08903",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Taryn Bollaro",
                            "role": "CONTACT",
                            "phone": "732-853-3229",
                            "email": "tb509@cinj.rutgers.edu"
                        },
                        {
                            "name": "Sanjay Goel, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.48622,
                        "lon": -74.45182
                    }
                },
                {
                    "facility": "Texas Oncology - Baylor Sammons Cancer Center",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75246",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Thomas Hutson, DO",
                            "role": "CONTACT",
                            "phone": "214-370-1000"
                        },
                        {
                            "name": "Stephanie Cannon",
                            "role": "CONTACT",
                            "phone": "972-490-2939"
                        },
                        {
                            "name": "Thomas Hutson, DO",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "NEXT Oncology Dallas",
                    "status": "RECRUITING",
                    "city": "Irving",
                    "state": "Texas",
                    "zip": "75039",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexis Praytor",
                            "role": "CONTACT",
                            "phone": "972-893-8800"
                        },
                        {
                            "name": "Shiraj Sen, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.81402,
                        "lon": -96.94889
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        }
    },
    "hasResults": false
}